Gastroenterology
Volume 134, Issue 5 , Pages 1342-1351 , May 2008

Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Allocation System and Predictors of Survival

  • George N. Ioannou

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
    • Research Enhancement Award Program, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
    • Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington
    • Corresponding Author InformationAddress requests for reprints to: George Ioannou, MD, MS, Veterans Affairs Puget Sound Health Care System, Gastroenterology, S-111-Gastro, 1660 S. Columbian Way, Seattle, Washington 98108. fax: (206) 764-2232.
    • ,
  • James D. Perkins

      Affiliations

    • Division of Transplantation, Department of Surgery, University of Washington, Seattle, Washington
    • ,
  • Robert L. Carithers Jr

      Affiliations

    • Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington

Received 20 August 2007 ,Accepted 7 February 2008.

References 

  1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  2. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311–322
  3. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–1440
  4. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–1086
  5. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403
  6. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998;228:479–490
  7. Yao FY, Roberts JP. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?. Liver Transpl. 2004;10:919–921
  8. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765–774
  9. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl. 2003;9:684–692
  10. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: prospective validation of expanded criteria. Hepatology. 2004;40:262A
  11. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: a 5-year prospective study validating expanded criteria applied to preoperative imaging. Hepatology. 2006;44:93A
  12. United Network for Organ Sharing. http://www.unos.orgAccessed July 20, 2007.
  13. Cox DR. Regression models and life tables. J Royal Stat Soc Ser B. 1972;34:187–202
  14. Omata M, Tateishi R, Yoshida H, et al. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology. 2004;127:S159–S166
  15. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–130
  16. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma (An analysis of 1000 cases). Cancer. 2005;103:1201–1209
  17. Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100:2708–2716
  18. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451–461
  19. Marsh JW, Dvorchik I, Bonham CA, et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?. Cancer. 2000;88:538–543
  20. Marsh JW, Dvorchik I. Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation?—yes. J Hepatol. 2005;43:558–562
  21. Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl. 2003;9:664–671
  22. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003;361:923–929

 This research was based on data derived from the United Network for Organ Sharing (UNOS) on January 10th, 2007. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services.

 Conflicts of interest: No conflicts of interest exist.

 Supported in part by Health Resources and Services Administration contract 231-00-0115 and American Liver Foundation and American Association for the Study of Liver Diseases Jan Albrecht Award (to G.N.I.).

PII: S0016-5085(08)00244-8

doi: 10.1053/j.gastro.2008.02.013

Gastroenterology
Volume 134, Issue 5 , Pages 1342-1351 , May 2008

Article Tools

* Image Usage & Resolution